The majority of food choices are shaped by what people can realistically afford and access. That menu of options is itself shaped by markets and public policy. ProVeg International’s food systems work uses these two levers: markets and public policy, to build the food-choice infrastructure that makes plant-rich options accessible, affordable, and easy to choose.
Opportunities to scale impact with more funding in 2027:
Total: ~$1-2.3M. This represents a portion of the total funding for each programme (current funding covers about a third for biotech, 50% for CPT). If you can only invest in one of these opportunities, we recommend investing in biotech first. It has the tightest timeline and, on our current estimates, the highest leverage.
You can support these programmes directly or email me at elizabeth.alvarez@proveg.org for more details.
Every day, billions of food choices are made. These decisions are much more influenced by the choice infrastructure of the defaults and available options people encounter than by individual preferences. Availability, affordability and positioning of foods can strongly shape these choices (Olafsson, 2026). Improving the placement, price and promotion of plant-based foods within shops results in increased sales of plant-based foods (2023 natural experiment in supermarkets). Similarly, when offering more vegetarian options in workplace cafeterias in a randomised trial, there was a 41% increase in vegetarian selections without negatively impacting total revenue (Becker, Garnett, Pechey et al., 2026). The same drivers apply to cultivated/fermented proteins; they are driven by taste, price and familiarity (Onwezen et al., 2021).
ProVeg aims to shift the global protein supply from animal to plant. We work with governments to change food policy and public funding for R&D, with retailers and caterers to put more plant-based proteins on sale, and with researchers and startups developing next-gen protein alternatives so better options exist in the first place. As these structures within the food system change to include more plant-based proteins and move away from animal ones, millions of individual food choices will change with them.
We see three high-impact opportunities for scaling, where marginal additional funding could help us achieve more than our current resources allow: alternative-protein and biotech policy across Europe, Corporate Protein Transition, and protein work in the Global South. All three are covered in this post in more detail, including what more funding would allow us to do through the first half of 2027. All three are at critical inflection moments, where consistent support can turn early progress into lasting wins and let us build on it.
Parts of this work are fortunate to receive EA-aligned backing. To name a few: the Netherlands Protein Tracker and our alternative protein work in China have received support from Coefficient Giving, and our work in China receives support from Giving Green, too. Nevertheless, we could absorb more funding for the projects mentioned in this post.
Helping governments invest in alternative-protein innovation is one of the higher-leverage opportunities for marginal funding right now. Making alternative proteins competitive with conventional meat and dairy requires substantial R&D investment. However, the sector remains relatively underfunded, and public funding has the potential to unblock critical challenges, mainly:
There is a compelling multiplier effect. Earlier this year, this assessment from Giving Green estimated that every $1 spent on advocacy could unlock $5 in public R&D funding. This public funding could consequently attract an additional $3.60 in private follow-on investment for every government dollar. Which, overall, represents a 18x multiplier on philanthropic capital combined (this higher-end figure is mainly due to private money being invested, and so should be interpreted as approximate upper values).
Europe presents great opportunities for food biotechnology right now. The EU has a strong scientific base but needs to do more to translate research into commercial products and manufacturing capacity. Decisions on its next seven-year research budget (2028–2034) and two new Biotech Acts will help determine whether Europe becomes a competitive centre for food biotechnology. We are working at EU and Member State level to secure public R&D investment, build political support and create workable regulatory frameworks.
What we’ve already done:
Biotech policy advocacy, as we fully envision it, will cost us a minimum of $1.5M in the next 12 months, working in Brussels and EU Member States. We need ~$100k for each Member State included in the project, and we estimate we need a minimum of 10 Member States engaged in 2027 for the project to deliver; with 14, we would maximise the return of the project.
With our current expected funding, we can cover around one third of the programme. Each additional Member State increases the national public research funding and the likelihood of a positive Member State vote on cultivated meat applications in November 2027.
Engaging with a few major retailers can influence the food choices available to millions of consumers. Several countries in Europe have markets dominated by a handful of supermarket chains. In Germany, the top 4 retailers account for >80% of the market (Edeka, Rewe, Schwarz, Aldi; Savills, 2024). In the Netherlands, >80% is accounted for by the top 5 retailers (58% by the top 2 retailers) (USDA, 2025). On average, across Europe, top grocers account for ~60% of national markets (Van Dam et al., 2021). Therefore, changes in the product mix, pricing and promotion within a few companies can lead to large changes in the consumption patterns within an entire nation.
We work with them to set and publish targets for plant-to-animal protein in their sales, raising the standard across the market. By lifting commitments and delivering on them this way, we shift buying behaviour at the level of the market, not one shopper at a time. We do this by:
How It’s Working So Far:
Our impact figures showed that in the Netherlands in 2024, the overall retail market shift influenced by our CPT programme avoided 1.2 to 1.3 million animal lives (15.03 to 16.80 lives per USD), and 83.17 to 84.52 million unscaled Suffering Adjusted Days (SADs) (1,074 to 1,091 unscaled SADs per USD).
Under ProVeg’s 40% more conservative attribution scenario, the programme avoided 465,596 to 520,642 animal lives (6.01 to 6.72 lives per USD), and 33.27 to 33.81 million unscaled SADs (429 to 436 unscaled SADs per USD).
Our work with European supermarkets costs around $2.9M per year. Our current funding covers about 50% of our ambition for the next 12 months, and doesn't cover growth to new markets.
What do we need?: $325k to $975k, to secure continuity and expansion into two more countries.
Over the next decade, low- and middle-income countries (LMICs) are expected to drive nearly all growth in farmed animal and fish consumption, while rising incomes and urbanisation shift diets toward more animal-source foods. Whereas the two European opportunities above seek to reduce existing overconsumption of animal-source foods, in these countries we are working to expand the range of credible ways to meet rising demand—so that intensive animal agriculture is not treated as the inevitable default. Our national offices in Nigeria, South Africa, India and Brazil are exploring interventions to support sustainable plant-rich pathways to meet that demand.
Each of these countries has different approaches that reflect their priorities and context. Food security often provides a common, practical entry point. This work will connect protein diversification with issues that governments already prioritise, including: nutrition, agricultural livelihoods, climate resilience, and domestic food production.
We want to turn our existing foundations in these local offices into concrete programmes; additional funding will help us:
What do we need?: Seed funding (~$150–300k, still being costed).
The total funding required would be roughly ~$1-2.3M. This is only a fraction of the total required: we currently have funding for a third of the $1.5M Biotech programme, and 50% of the $2.9M CPT programme.
If you can only back one, here's how we'd weigh them:
The figures given here are our estimations based on current budgets. There are some uncertainties in these values. The biotech value is an estimate depending on votes in the EU in 2027. The value of CPTs is an estimate from the top down, so we include a conservative value for attribution (40%) as well as the market-level estimate.
If you are interested in supporting any of these programmes, we are very happy to provide more specific details and the cost-effectiveness models available. Our CPT impact models build on AIM's encouraging estimates of the protein shift, and we have done some modelling of impacts from biotech. We don't yet have numbers for the Global South; this is something that seed funding will be used for.
If any of these programmes resonate with you and you want to support them, the simplest way is to donate directly, adding the details on your preferred designation in the form.
We have a few different ways to give, including workplace giving and some tax-deductible routes in several countries, depending on your location. If you are thinking about a larger gift or would like more detailed information, email me at elizabeth.alvarez@proveg.org.
I'll be in the comments section in the upcoming days; feel free to ask for more details!
_______
Notes on authorship: This post contains outputs from programmes, data, and models created by members across teams and offices of ProVeg International. I wrote this post, and any mistakes are my own.
All text is human-written. I lightly used an LLM to proofread this post and create charts from our data. The analysis, data, and conclusions are ProVeg's own.